Answers are grounded in this paper and cite their sources.
Estimates of the cost of treating common illnesses are important for allocating prevention and research funds optimally, for understanding the impact of each disease on federal and state budgets, and for quantifying the costs of disease-specific insurance expansions and programs. Existing estimates of the cost of cancer care in the U.S. rely on several different approaches. Although total spending estimates are similar, each approach entails strong assumptions and may produce inaccurate estimates for subpopulations of interest. Brown and Fintor calculated the quantity of services consumed by cancer patients using site-specific surveys, such as the National Hospital Discharge Survey, then multiplied the share of services (e.g., hospital days, office visits) attributable to cancer by the corresponding expenditure total for the service category in the National Health Accounts. Summing over service types produces an estimate of the total cost of cancer care: $27 billion in 1990 and $41 billion in 1995. This method assumes that per-day or per-visit reimbursements for cancer services do not differ from payments for other types of care. It also assumes that all services related to cancer care are coded as such, although cancer patients experience symptoms and side effects that may require treatment outside of visits for curative care. A second method of estimating the cost of cancer care is described by Brown et al. First, using Medicare claims data, by cancer type, those authors estimate the cost of three distinct phases of cancer care: the initial care phase, the continuing care phase, and the terminal care phase. Second, they classify patients in the SEER data according to cancer phase and cancer type by month. Finally, they impute phase-specific costs to each patient; sum over patients; and, after a number of adjustments, arrive at a national, annual estimate of about $40 billion (1996 U.S. dollars). An important assumption embedded in this final step is that Medicare expenditures and reimbursements for cancer care are a good proxy for spending by and payments from private payers. However, private payers generally offer more generous benefits than Medicare, and reimbursement rates tend to be higher. 883
No takes yet. Share an insight, caveat, or question.
Howard et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: